Drug review decisions
Last updated on November 7, 2024On this page:
- Drug review results search tool: Find out if a drug is under review, where it is in the review process, if and when PharmaCare decided to cover it, and under which PharmaCare plan(s) it's covered
- Drug decision summaries: Drugs reviewed by PharmaCare, with a summary noting the reasons they were or were not covered
- Therapy and program reviews: Reviews of specific programs and conditions, plus supporting information such as drug decision summaries, clinical and pharmacoeconomic evidence reports, and Drug Benefit Council recommendations
Use this tool to search:
- All drugs reviewed by CDA (formerly CADTH) and submitted to the Ministry of Health for consideration
- All drug reviews completed by the Ministry since 2005
- Brand-name drugs currently under review by the Ministry and CDA (formerly CADTH), with results including:
- the drug's brand name, chemical name, and manufacturer
- the drug's indication (the condition it treats)
- the date the drug was submitted to the Ministry
- the date the drug was discussed by the Drug Benefit Council (DBC)
- whether the drug was reviewed by CDA (formerly CADTH)
- the date CDA (formerly CADTH) made its recommendation
- the drug's PharmaCare program status (e.g., under review, non-benefit)
- the date the Ministry made its decision
Generic drugs are not included.
To search for drugs not found with this search tool, try using the PharmaCare formulary search.
Go to the Drug review results search tool
Any column in this table can be alphabetically sorted. Drugs that have not been reviewed or that were reviewed before 2008 will not appear in this table.
| Generic name | Brand name | Indication | PharmaCare decision dates and summaries (PDF) |
|---|---|---|---|
| abatacept (SQ) | Orencia® | rheumatoid arthritis | February 25, 2014 |
| abobotulinumtoxinA | Dysport Therapeutic™ | cervical dystonia (spasmodic torticollis) and focal spasticity | February 26, 2019 |
| abrocitinib | Cinibqo™ | moderate to severe atopic dermatitis | November 23, 2023 |
| avatrombopag | Doptelet® | thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) | November 7, 2024 |
| aclidinium | Tudorza™, Genuair™ | chronic obstructive pulmonary disease (COPD) | September 30, 2014 |
| aclidinium bromide-formoterol fumarate dehydrate | Duaklir™, Genuair® | chronic obstructive pulmonary disease (COPD) | April 5, 2016 |
| adalimumab | Humira® | difficult-to-treat Crohn's disease | September 9, 2008 |
| adalimumab | Humira® | juvenile idiopathic arthritis | February 25, 2014 |
| adalimumab | Humira® | ulcerative colitis | June 20, 2017 |
| adalimumab | Humira® | hidradenitis suppurativa (HS) | April 18, 2017 and March 6, 2018 |
| adalimumab | Abrilada®, Amgevita®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi™, Yuflyma™ | rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa for adults, and plaque psoriasis | April 7, 2021, September 30, 2021 and August 18, 2022 |
| adalimumab (biosimilars) | Abrilada®, Amgevita®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi™, Yuflyma™ | active non-infectious uveitis in patients aged 2 years and older | July 3, 2024 |
| adefovir | Hepsera® | chronic hepatitis B | November 27, 2018 |
| alemtuzumab | Lemtrada™ | relapsing-remitting multiple sclerosis (RRMS) | February 6, 2018 |
| alendronate and risedronate | Fosamax®, Actonel®, generics | primary prevention of osteoporotic bone fractures | January 17, 2023 |
| alirocumab | Praluent™ | treatment of high-risk adult patients who have had prior cardiovascular (CV) events and require additional lowering of low density lipoprotein cholesterol (LDL-C) | January 28, 2020 |
| alogliptin | Nesina™ | type 2 diabetes mellitus | May 5, 2015 |
| alogliptin-metformin | Kazano™ | type 2 diabetes mellitus | May 5, 2015 |
| amifampridine | Ruzurgi® | Lambert-Eaton myasthenic syndrome (LEMS) | March 28, 2023 |
| amifampridine phosphate | Firdapse® | Lambert-Eaton Myasthenic Syndrome (LEMS) | September 7, 2023 |
| apixaban | Eliquis® | stroke prophylaxis in atrial fibrillation | September 19, 2013 |
| apixaban | Eliquis® | prevention of venous thromboembolic events | December 10, 2013 |
| apixaban | Eliquis® | thromboembolic events (venous), treatment and prevention of recurrence | April 5, 2016 |
| apomorphine | Movapo™ | advanced Parkinson’s disease | November 26, 2019 |
| apomorphine hydrochloride | Kynmobi® | “OFF” episodes in adults with Parkinson’s disease | June 27, 2022 |
| apremilast | Otezla® | moderate to severe plaque psoriasis | October 10, 2017 |
| apremilast | Otezla® | psoriatic arthritis | October 10, 2017 |
| aprepitant | Emend® | prevention of vomiting in patients with cancer | March 16, 2010 |
| aripiprazole | Abilify® | major depressive disorder (MDD) | April 14, 2015 |
| aripiprazole monohydrate | Abilify Maintena™ | schizophrenia | August 11, 2015 |
| asunaprevir | Sunvepra™ | chronic hepatitis C (CHC) | March 21, 2017 |
| atomoxetine | Strattera® and generics | attention deficit hyperactivity disorder (ADHD) | April 18, 2017 and June 9, 2020 |
| avacopan | Tavneos® | for the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-AV) in combination with standard background therapy including glucocorticoids | February 27, 2024 |
| avalglucosidase alfa | Nexviazyme™ | late-onset Pompe disease (LOPD) | October 25, 2023 |
| azelastine hydrochloride – fluticasone propionate | Dymista® | moderate to severe seasonal allergic rhinitis and associated ocular symptoms | September 29, 2015 |
| azilsartan | Edarbi | hypertension, essential | July 29, 2014 |
| azilsartan | Edarbyclor | hypertension, essential | July 29, 2014 |
| baricitinib | Olumiant™ | moderate to severe rheumatoid arthritis in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drug (DMARD) | November 17, 2020 |
| belimumab | Benlysta® | reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) | July 6, 2021 |
| benralizumab | Fasenra® | severe eosinophilic asthma | April 1, 2020 |
| berotralstat | Orladeyo® | hereditary agioedema (HAE) | November 7, 2024 |
| bimekizumab | Bimzelx™ | moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy | January 31, 2023 |
| boceprevir | Victrelis™ | HIV/hepatitis C | October 10, 2013 |
| brexpiprazole | Rexulti® | schizophrenia | December 17, 2019 |
| brinzolamide-brimonidine | Simbrinza® | glaucoma and ocular hypertension | October 27, 2015 |
| brivaracetam | Brivlera® | epilepsy, partial-onset seizures | September 3, 2021 |
| brodulamab | Siliq™ | plaque psoriasis | November 27, 2018 |
| brolucizumab | Beovu® | neovascular (wet) age-related macular degeneration (nAMD) | July 26, 2022 |
| budesonide | Cortiment®MMX | induction of remission in patients with active, mild to moderate ulcerative colitis | June 13, 2017 |
| budesonide | Jorveza™ | induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE) |
August 18, 2022 |
| budesonide-glycopyrronium-formoterol | Breztri® Aerosphere® | Chronic Obstructive Pulmonary Disease (COPD) | November 2, 2022 |
| buprenorphine extended release | Sublocade™ | opioid use disorder | April 30, 2020 |
| buprenorphine-naloxone | Suboxone® | opioid drug dependence in adults | October 13, 2015 |
| buprenorphine hydrochloride | Probuphine™ | management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support | February 25, 2020 |
| canagliflozin-metformin | Invokamet® | type 2 diabetes mellitus (T2DM) | February 18, 2022 |
| canakinumab | Ilaris® | active systemic juvenile idiopathic arthritis (sJIA) in patients aged two years and older | January 10, 2017 |
| caplacizumab | Cablivi® | powder for solution for intravenous or subcutaneous injection (11mg/vial) | May 26, 2023 |
| certolizumab pegol | Cimzia® | arthritis, psoriatic | February 19, 2016 |
| certolizumab pegol | Cimzia® | ankylosing spondylitis | February 19, 2016 |
| ciprofloxacin + dexamethasone (ear drops) | Ciprodex® | acute otitis media with otorrhea and otitis externa | January 16, 2009 and February 6, 2021 |
| cladribine | Mavenclad® | relapsing remitting multiple sclerosis (RRMS) | January 25, 2022 |
| clopidogrel (1) | Plavix® | after drug-eluting stent insertion | February 18, 2008 |
| clopidogrel (2) | Plavix® | acute coronary syndrome | March 20, 2020 |
| clostridium botulinum neurotoxin type A, with complexing proteins | Xeomin® | muscle spasticity | June 15, 2010 |
| colchicine | Myinfla™ | add-on therapy to standard of care for the reduction of atherothrombotic events in patients who had a myocardial infarction | July 19, 2022 |
| colesevelam hydrochloride | Lodalis | hypercholesterolemia | June 13, 2013 |
| collagenase clostridium histolyticum | Xiaflex™ | Dupuytren’s contracture with a palpable cord | March 25, 2014 |
| continuous glucose monitoring (CGM) system | Dexcom G5® and Dexcom G6® | diabetes mellitus | June 1, 2021 |
| continuous glucose monitor (CGM) system | Guardian™ Sensor (3) glucose sensor, GuardianLink (3) transmitter, and Guardian Connect CGM system | diabetes mellitus | June 1, 2021 |
| continuous glucose monitor - transmitter | Dexcom G6® | diabetes mellitus | June 1, 2021 |
| continuous glucose monitoring (CGM) system | Dexcom G7® | diabetes mellitus | November 7, 2023 |
| crisaborole | Eucrisa™ | atopic dermatitis | January 14, 2020 |
| cyclosporine | Verkazia™ | severe vernal keratoconjunctivitis in children four years of age and older | March 23, 2021 |
| daclatasvir | Daklinza™ | chronic hepatitis C (CHC) | February 4, 2020 |
| dalbavancin hydrochloride | Xydalba® | treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) | September 17, 2024 |
| dapagliflozin | Forxiga® | heart failure with reduced ejection fraction (HFrEF) | January 11, 2022 |
| deferiprone | Ferriprox™ | transfusional iron overload due to thalassemia syndromes | October 25, 2016 |
| deferiprone | Ferriprox™ | treatment of patients with transfusional iron overload due to sickle cell disease (SCD) or other anemias | March 14, 2024 |
| delta-9-tetrahydrocannabinol + cannabidiol (1) | Sativex® | adjunctive neuropathic pain relief in multiple sclerosis | December 23, 2008 |
| delta-9-tetrahydrocannabinol + cannabidiol (2) | Sativex® | adjunctive pain relief in advanced cancer | December 23, 2008 |
| denosumab | Prolia® | men with osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy | February 14, 2017 |
| denosumab | Prolia® | women with breast cancer taking aromatase inhibitors without a documented fracture men with prostate cancer taking androgen deprivation therapy without a documented fracture |
January 17, 2023 |
| denosumab | Prolia® | secondary prevention of osteoporotic fractures in patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min | January 17, 2023 |
| denosumab | Xgeva® | prevention of skeletal-related events due to bone metastases from solid tumors | January 17, 2017 |
| denosumab | Jubbonti® and Wyost™ | Jubbonti: osteoporosis Wyost: hypercalcemia of malignancy (PharmaCare Plan P palliative care benefit) |
August 29, 2024 |
| deucravacitinib | Sotyktu™ | treatment of adult patients with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy | July 25, 2024 |
| dexamethasone | Ozurdex® | diabetic macular edema | February 26, 2019 and August 17, 2023 |
| dextroamphetamine-amphetamine (mixed amphetamine salts) | Adderall XR® and generics | attention deficit hyperactivity disorder (ADHD) | April 18, 2017 and June 9, 2020 |
| difelikefalin | Korsuva® | treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis | April 30, 2024 |
| dimethyl fumerate | Tecfidera™ | multiple sclerosis, relapsing | June 24, 2014 |
| triheptanoin | Dojolvi™ | long-chain fatty acid oxidation disorders | May 23, 2023 |
| doxycycline | Apprilon® | rosacea | January 28, 2014 |
| dulaglutide | Trulicity® | type 2 diabetes | March 13, 2020 |
| duloxetine | generics | neuropathic pain | November 27, 2018 |
| dupilumab | Dupixent® | atopic dermatitis | January 22, 2019 and May 11, 2021 |
| dupilumab | Dupixent® | maintenance treatment for severe asthma | September 20, 2022 and October 17, 2023 |
| eculizumab | Soliris® | generalized myasthenia gravis (gMG) in adult patients | Feburary 10, 2023 |
| eculizumab | Soliris® | hemolytic-uremic syndrome, atypical | January 14, 2014 |
| eculizumab | Soliris® | neuromyelitis optica spectrum disorder (NMOSD) | February 10, 2023 |
| edaravone | Radicava™ | amyotrophic lateral sclerosis (ALS) | August 19, 2020 |
| edoxaban | Lixiana® | stroke and blood clot prevention in atrial fibrillation; treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) | March 26, 2019 |
| efinaconazole | Jublia™ | fungal infection (onychomycosis) caused by certain fungi (Trichophyton species) | March 3, 2020 |
| elbasvir-grazoprevir | Zepatier® | chronic hepatitis C (CHC) | February 4, 2020 |
| elexacaftor/tezacaftor/ivacaftor | Trikafta® | treatment of cystic fibrosis in patients aged two years and older who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to Trikafta based on clinical and/or in vitro data | November 6, 2024 |
| elosulfase alfa | Vimizim™ | mucopolysaccharidosis type IVA (MPS IVA or Morquio A syndrome) | September 22, 2015 |
| eltrombopag | Revolade® | chronic hepatitis C associated thrombocytopenia (low platelet counts) | July 14, 2015 |
| eluxadoline | Viberzi™ | irritable bowel syndrome | June 11, 2019 |
| empagliflozin | Jardiance™ | type 2 diabetes mellitus (T2DM) | May 27, 2019 |
| enoxaparin biosimilars | Inclunox®, Inclunox® HP, Noromby®, Noromby® HP, Redesca®, Redesca® HP | treatment and prophylaxis of venous thromboembolism (VTE) | March 22, 2022 |
| enoxaparin biosimilars | Elonox®, Elonox® HP | treatment and prophylaxis of venous thromboembolism (VTE) | June 1, 2023 |
| entecavir | Baraclude® | chronic hepatitis B | November 27, 2018 |
| eplerenone | Inspra® | heart failure, NYHA class II | November 18, 2014 |
| eptinezumab | Vyepti® | prevention of migraine in adults who have at least 4 migraine days per month | April 23, 2024 |
| erenumab | Aimovig® | prevention of chronic migraine in adults | March 29, 2022 |
| esketamine hydrochloride | Spravato® | major depressive disorder (MDD) in adults | August 3, 2021 |
| eslicarbazepine acetate | Afinitor® | epilepsy, partial-onset seizures | November 10, 2015 |
| estradiol | Imvexxy™ | treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy | May 14, 2024 |
| estradiol/progesterone | Bijuva™ | treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women with an intact uterus | July 6, 2023 |
| etanercept | Brenzys™; Erelzi™; Enbrel® | rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis | May 27, 2019 |
| etanercept | Erelzi™ | psoriatic arthritis | April 9, 2019 |
| etanercept | Brenzys™ | rheumatoid arthritis (RA), ankylosing spondylitis (AS), polyarticular juvenile idiopathic arthritis, psoriatic arthritis | July 18, 2017, February 18, 2021 (criteria expansion) |
| etanercept | Erelzi™ | rheumatoid arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis | November 14, 2017 |
| etanercept | Brenzys™, Erelzi™ | plaque psoriasis | April 7, 2021 |
| etanercept | Rymti® | moderately to severely active rheumatoid arthritis (RA), reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 to 17 years, reducing signs and symptoms of active ankylosing spondylitis (AS), inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA), and treatment of chronic moderate to severe plaque psoriasis (PsO) in adults | June 25, 2024 |
| etidronate (in combination with calcium carbonate) | Didrocal ACT-etidrocal |
prevention of fractures due to osteoporosis | February 19, 2019 |
| etonogestrel | Nexplanon® | prevention of pregnancy for up to three years | December 7, 2021 |
| everolimus (1) | Afinitor® | renal angiomyolipoma associated with tuberous sclerosis complex (TSC) | August 12, 2014 |
| everolimus (2) | Afinitor® | subependymal giant cell astrocytoma (SEGA), a brain tumour associated with a genetic condition called tuberous sclerosis complex (TSC) | July 28, 2015 |
| evolocumab | Repatha® | clinical artherosclerotic cardiovascular disease (ASCVD) | March 10, 2020 |
| evolocumab | Repatha® | heterozygous familial hypercholesterolemia | December 18, 2018 |
| exenatide | Byetta | type 2 diabetes mellitus (T2DM) | June 20, 2013 |
| elexacaftor/tezacaftor/ivacaftor | Trikafta® | cystic fibrosis in patients aged 2-5 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene | December 14, 2023 |
| ezetimibe | Ezetrol® | hypercholesterolemia | December 18, 2018 |
| ezetimibe | Ezetrol® | high cholesterol in patients with specific variants of NPC1L1 protein | September 27, 2007 |
| fampridine | Fampyra® | multiple sclerosis, improve walking ability | June 20, 2013 |
| fentanyl buccal/sublingual | Fentora® | management of breakthrough pain in adult cancer patients with difficulty swallowing or inadequate pain relief/intolerance/contraindication to morphine, oxycodone or hydromorphone | May 16, 2017 |
| fesoterodine fumarate | Toviaz® | overactive bladder | August 4, 2016 |
| fidaxomicin | Dificid® | Clostridium difficile infection | February 25, 2014 |
| filgrastim | Grastofil® | prevention/treatment of neutropenia | January 31, 2017 |
| filgrastim | Grastofil® | primary prophylaxis of febrile neutropenia in cancer patients receiving potentially curative myelosuppressive chemotherapy regimens where the risk of febrile neutropenia is ≥ 20% | October 16, 2018 |
| filgrastim | Grastofil® | pre-filled sterile solution for injection | January 31, 2017 |
| filgrastim | Nivestym™ | prevention/treatment of neutropenia | March 22, 2022 |
| filgrastim | Nypozi™ | prevention and treatment of neutropenia | May 14, 2024 |
| finerenone | Kerendia® | as an adjunct to standard of care therapy to delay progression of kidney disease and to reduce the risk of major adverse cardiovascular events (cardiovascular [CV] death, non-fatal myocardial infarction, non-fatal stroke) and hospitalization for heart failure in adults with chronic kidney disease (CKD) and type 2 diabetes (T2D) | February 27, 2024 |
| flash glucose monitoring (FGM) system | Freestyle® Libre and Freestyle Libre 2 | diabetes mellitus | June 1, 2021 |
| flash glucose monitoring (FGM) system | Freestyle® Libre 2 | diabetes mellitus | August 1, 2023 |
| fluorouracil and salicyclic acid | Actikerall™ | slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients | March 20, 2018 |
| fluticasone furoate | Arnuity™; Ellipta® | asthma | September 13, 2016 |
| fluticasone furoate-umeclidinium-vilanterol | Trelegy® Ellipta® | chronic obstructive pulmonary disease (COPD) | July 7, 2020 |
| fluticasone furoate-vilanterol | Breo®; Ellipta® | chronic obstructive pulmonary disease (COPD) | May 15, 2015 |
| fluticasone furoate-vilanterol | Breo®; Ellipta® | asthma | September 13, 2016 |
| fluticasone propionate | Aermony RespiClick™ | asthma in patients 12 years or older | February 11, 2020 and August 12, 2021 |
| fluticasone propionate/salmeterol xinafoate | Arbesda RespiClick™ | asthma in patients 12 years or older | February 11, 2020 |
| foslevodopa/foscarbidopa | Vyalev™ | treatment of advanced Parkinson’s Disease (aPD) | August 20, 2024 |
| fosfomycin | Monurol® | uncomplicated urinary tract infections | March 24, 2015 |
| fostamatinib | Tavalisse® | chronic immune thrombocytopenia (ITP) | January 31, 2023 |
| fremanezumab | Ajovy® | prevention of migraine in adults | March 29, 2022 |
| galcanezumab | Emgality® | prevention of migraine | April 11, 2023 |
| givosiran | Givlaari™ | treatment of acute hepatic porphyria (AHP) in adults | June 22, 2023 |
| glatiramer acetate | Copaxone® | relapsing remitting multiple sclerosis. | March 17, 2020 |
| glatiramer acetate | Glatect™ | relapsing remitting multiple sclerosis | November 27, 2018 |
| glecaprevir-pibrentasvir | Maviret™ | chronic hepatitis C | March 21, 2019, January 29, 2019, June 11, 2020 and April 14, 2021 |
| gliclazide | Diamicron® | type 2 diabetes | July 8, 2008 |
| glucagon nasal powder | Baqsimi™ | severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness prevents the ingestion of oral carbohydrates | April 5, 2022 |
| glycopyrrolate | Cuvposa™ | reduce drooling caused by certain health problems in patients 3 to 18 years of age | February 28, 2023 |
| glycopyrronium | Seebri® | chronic obstructive pulmonary disease (COPD) | September 19, 2013 |
| golimumab | Simponi® | ulcerative colitis | May 31, 2016 |
| golimumab | Simponi®; Intravenous (IV) | rheumatoid arthritis (RA) | May 31, 2016 |
| grass pollen allergen extract | Oralair™ | allergic rhinitis (grass pollen) | October 31, 2013 |
| guanfacine | Intuniv XR® | attention deficit hyperactivity disorder (ADHD) | April 18, 2017 |
| guselkumab | Tremfya® and Tremfya® One-Press™ | moderate to severe plaque psoriasis in adults | May 5, 2020 |
| guselkumab | Tremfya® and Tremfya® One-Press™ | for the treatment of adult patients with active psoriatic arthritis | November 28, 2023 |
| halobetasol propionate and tazarotene | Duobrii™ | plaque psoriasis | April 19, 2022 |
| icatibant | Firazyr® | angioedema | February 6, 2018 |
| icosapent ethyl | Vascepa® | prevention of cardiovascular events in statin-treated patients | July 6, 2023 |
| icosapent ethyl | Vascepa® | prevention of cardiovascular events in statin-treated patients | February 6, 2024 |
| imiquimod | Aldara® | actinic keratosis on the face or balding scalp | June 28, 2010 |
| inclisiran | Leqvio™ | lowering of low density lipoprotein cholesterol (LDL-C) | September 27, 2022 |
| incobotulinumtoxinA | Xeomin® | chronic sialorrhea associated with neurological disorders in adults | February 14, 2023 |
| indacaterol | Onbrez® | chronic obstructive pulmonary disease (COPD), maintenance bronchodilator treatment | May 30, 2013 |
| indacaterol-glycopyrronium | Ultibro®; Breezhaler® | chronic obstructive pulmonary disease (COPD) | June 2, 2015 |
| indacaterol-glycopyrronium-mometasone furoate | Enerzair® Breezhaler® | maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months |
June 14, 2022 |
| indacaterol-mometasone furoate | Atectura® Breezhaler® | maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease |
June 14, 2022 |
| infliximab | Avsola® | rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and plaque psoriasis | February 18, 2021 |
| infliximab | Inflectra®; Renflexis™; Remicade® | ankylosing spondylitis,psoriatic arthritis, rheumatoid arthritis | May 27, 2019 |
| infliximab | Inflectra™ | ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis | February 19, 2016 |
| infliximab | Inflectra®; Renflexis™ | Crohn’s disease and ulcerative colitis | September 5, 2019 |
| infliximab | Remsima™ SC | rheumatoid arthritis in adults | June 14, 2022 |
| ingenol mebutate | Picato® | keratosis, actinic | June 5, 2014 |
| inotersen | Tegsedi™ | polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR) | October 24, 2024 |
| insulin aspart | Kirsty® | type 1 & 2 diabetes mellitus | January 24, 2023 |
| insulin aspart and insulin lispro | Trurapi®; Admelog® | type 1 & 2 diabetes mellitus | November 30, 2021 |
| insulin degludec | Tresiba® | type 1 & 2 diabetes mellitus | June 12, 2008 |
| insulin degludec and liraglutide | Xultophy® | type 2 diabetes | March 13, 2020 |
| insulin glargine | Basaglar®; Lantus® | type 1 & 2 diabetes mellitus | May 27, 2019 |
| insulin glargine | Semglee® | type 1 or type 2 diabetes mellitus | May 25, 2023 |
| insulin glargine and lixisenatide | Soliqua™ | type 2 diabetes | March 13, 2020 |
| insulin glulisine | Apidra™ | type 1 & 2 diabetes mellitus | June 1, 2009 |
| interferon beta-1a | Rebif® | clinically isolated syndrome (MS) | March 25, 2014 |
| interferon beta-1b injection | Betaseron® | early treatment before a definite diagnosis of multiple sclerosis | July 8, 2008 |
| iron isomaltoside 1000 | Monoferric® | iron deficiency anemia (IDA) | October 6, 2021 |
| isavuconazole | Cresemba™ | invasive aspergillosis (IA) and invasive mucormycosis (IM) | February 23, 2021 |
| isotretinoin | Epuris™ | severe acne | October 10, 2013 |
| ivabradine | Lancora™ | heart failure | October 30, 2018 |
| ivacaftor | Kalydeco™ | cystic fibrosis (CF) in patients with G551D mutation | March 11, 2015 |
| ivermectin | Rosiver™ | inflammatory lesions of rosacea in adults 18 years of age and older | September 27, 2016 |
| ixekizumab | Taltz™ | ankylosing spondylitis | March 15, 2022 |
| ixekizumab | Taltz™ | psoriatic arthritis | May 27, 2019 |
| ixekizumab | Taltz™ | severe plaque psoriasis | March 6, 2018 |
| lamotrigine | Lamictal® and generics | bipolar disorder | November 12, 2019 |
| latanoprost | Monoprost® | reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension | January 28, 2020 |
| latanoprostene bunod | Vyzulta® | reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension | October 30, 2020 |
| ledipasvir-sofosbuvir | Harvoni™ | chronic hepatitis C (CHC) | February 4, 2020 |
| lemborexant | Dayvigo® | treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance | March 14, 2024 |
| letermovir | Prevymis™ | prophylaxis of cytomegalovirus (CMV) infection | May 18, 2021 |
| levodopa + carbidopa + entacapone | Stalevo® | hard-to-treat Parkinson’s disease | June 5, 2009 |
| levodopa-carbidopa | Duodopa® | advanced Parkinson's disease | December 10, 2020 |
| levofloxacin | Levaquin® | short-course airway infections | January 14, 2009 |
| levofloxacin | Quinsair | cystic fibrosis | October 16, 2018 |
| linagliptin; linagliptin-metformin | Trajenta®, Jentadueto™ | type 2 diabetes mellitus | August 5, 2014 |
| lipase-amylase-protease | Creon Minimicrospheres® 35 | pancreatic exocrine insufficiency (PEI) attribute to cystic fibrosis (CF), chronic pancreatitis (CP), or any other medically defined pancreatic disease that might require pancreatic enzyme therapy | August 19, 2021 |
| liraglutide | Saxenda® | adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients | April 26, 2022 |
| lisdexamfetamine | Vyvanse® | attention deficit hyperactivity disorder (ADHD) | April 18, 2017 and June 9, 2020 |
| lixisenatide | Adlyxine™ | type 2 diabetes mellitus | June 12, 2018 |
| lomitapide | Juxtapid™ | to reduce high cholesterol caused by homozygous familial hypercholesterolemia (HoFH) | June 23, 2015 |
| lovastatin + niacin | Advicor® | high cholesterol | March 3, 2008 |
| lumacaftor-ivacaftor | Orkambi | cystic fibrosis (CF) in patients with F508del mutation | March 21, 2017 |
| lumasiran | Oxlumo® | treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients | July 16, 2024 |
| lurasidone | Latuda™ | schizophrenia | September 19, 2013 and September 16, 2014 |
| lurasidone | Latuda™ | for the management of schizophrenia and for the acute management of depressive episodes associated with bipolar I disorder | March 7, 2024 |
| luspatercept | Reblozyl® | lyophilized powder for solution for subcutaneous injection | March 14, 2023 |
| luspatercept | Reblozyl® | lyophilized powder for solution for subcutaneous injection | March 14, 2023 |
| macitentan | Opsumit™ | pulmonary arterial hypertension | January 26, 2016 |
| macitentan-tadalafil | Opsynvi® | pulmonary arterial hypertension (PAH), in World Health Organization (WHO) Functional Class (FC) II or III patients | September 14, 2022 |
| mecasermin | Increlex® | The treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (SPIGFD) | April 27, 2023 |
| medroxyprogesterone acetate | Depo-Provera® | prevention of pregnancy and treatment of endometriosis | April 19, 2022 |
| mepolizumab | Nucala™ | severe eosinophilic asthma | October 29, 2019 |
| mepolizumab | Nucala™ | asthma | May 26, 2020 |
| mesalazine | Mezera™ | ulcerative colitis and ulcerative proctitis | February 26, 2019 |
| methadone | Metadol-D® | opioid use disorder | March 26, 2019 |
| methylphenidate (extended-release) | Concerta® and generics | attention deficit hyperactivity disorder (ADHD) | April 18, 2017 and June 9, 2020 |
| methylphenidate (controlled-release) | Biphentin® | attention deficit hyperactivity disorder (ADHD) | April 18, 2017 |
| mifepristone and misoprostol | Mifegymiso® | medical termination of a developing intra-uterine pregnancy with a gestational age up to 49 days as measured from the first day of the last menstrual period (LMP) in a presumed 28-day cycle | July 11, 2017 |
| mirabegron | Myrbetriq® | overactive bladder | August 4, 2016 |
| moxifloxacin | Avelox® | airway infections | January 15, 2009 |
| mycophenolate mofetil | Teva-Mycophenolate® | bullous pemphigoid and autoimmune hepatitis | November 26, 2019 |
| naltrexone hydrochloride and bupropion hydrochloride | Contrave® | chronic weight management in obese adults with a body mass index (BMI) of 30 kg/m2 or greater or overweight adults with a BMI of 27 kg/m2 or greater who have at least one weight-related condition |
May 25, 2021 |
| natalizumab | Tysabri® | relapsing remitting multiple sclerosis | March 26, 2019 |
| nebivolol | Bystolic® | hypertension, essential | March 25, 2014 |
| netupitant-palonosetron | Akynzeo™ | prevention of chemotherapy-induced nausea and vomiting (CINV) in adult patients | November 26, 2019 |
| nintedanib | Ofev® | idiopathic pulmonary fibrosis (IPF) | February 6, 2018 |
| nintedanib | Ofev® | chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype also known as progressive fibrosing ILD (PF-ILD) or progressive pulmonary fibrosis (PPF) |
June 7, 2022 |
| nirmatrelvir-ritonavir | Paxlovid™ | mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death | Mary 28, 2024 |
| nusinersen | Spinraza® | adult type 2 and type 3 spinal muscular atrophy (SMA) | December 15, 2022 |
| obeticholic acid | Ocaliva® | primary biliary cholangitis | October 30, 2018 |
| ocrelizumab | Ocrevus® | relapsing remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS) | August 20, 2020 |
| ocriplasmin | Jetrea® | symptomatic vitreomacular adhesion | January 27, 2015 |
| ofatumumab | Kesimpta™ | elapsing remitting multiple sclerosis (RRMS) | June 27, 2022 |
| omalizumab | Xolair® | chronic idiopathic urticarial | November 29, 2016 and April 28, 2020 |
| ombitasvir-paritaprevir-ritonavir and dasabuvir | Holkira™Pak | chronic hepatitis C (CHC) genotype 1 infection | July 28, 2015 |
| onabotulinumtoxinA | Botox® | prevention of headaches in adults with chronic migraine | November 18, 2014 |
| onabotulinumtoxinA | Botox® | overactive bladder | February 26, 2019 |
| onabotulinumtoxinA | Botox® | prophylaxis of headaches in adults with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) | March 29, 2022 |
| ospemifene | Osphena® | dyspareunia (pain with intercourse) and/or vaginal dryness, associated with of postmenopausal vulvovaginal atrophy | May 30, 2023 |
| oxybutynin (controlled-release) | Uromax® | overactive bladder | February 27, 2008 |
| ozanimod | Zeposia® | adult patients with the relapsing and remitting form of multiple sclerosis (RRMS) | July 26, 2022 |
| ozanimod | Zeposia® | for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic agent | January 16, 2024 |
| ozenoxacin | Ozenax™ | impetigo | April 9, 2019 |
| palonosetron hydrochloride | Aloxi® capsule | nausea and vomiting (chemotherapy induced) prevention | October 31, 2013 |
| palonosetron hydrochloride | Aloxi® injection | nausea and vomiting (chemotherapy induced) prevention | October 31, 2013 |
| pasireotide | Signifor® | treatment of adult patients with Cushing's disease for whom medical therapy is appropriate | September 1, 2015 |
| patiromer | Veltassa® | hyperkalemia in patients with chronic kidney disease stage 3-4 on Renin-Angiotensin Aldosterone System Inhibitors (RAASi) | July 19, 2022 |
| pegcetacoplan | Empaveli™ | treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor | March 6, 2024 |
| pegfilgrastim | Fulphila™ | decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs | February 11, 2020 |
| pegfilgrastim | Lapelga | decrease infection with febrile neutropenia for non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs | July 9, 2019 |
| pegfilgrastim | Nyvepria™ | decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs | May 10, 2022 |
| pegfilgrastim | Ziextenzo® | decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs | May 10, 2022 |
| peginterferon beta-1a | Plegridy | multiple sclerosis (MS), relapsing | August 4, 2016 |
| pegvisomant | Somavert® | last line of treatment for acromegaly | January 14, 2014 |
| perampanel | Fycompa™ | epilepsy, partial onset seizures | August 15, 2014 and September 24, 2020 |
| perindopril arginine-amlodipine | Viacoram® | essential hypertension | July 25, 2017 |
| pirfenidone | Esbriet™ | idiopathic pulmonary fibrosis (IPF) | January 14, 2014 |
| pitolisant hydrochloride | Wakix® | treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy | August 15, 2023 |
| prasugrel | generics | prevention of atherothrombotic events in patients with acute coronary syndrome | December 14, 2021 |
| prasterone | Intrarosa™ | postmenopausal vulvovaginal atrophy | May 30, 2023 |
| propiverine | Mictoryl® | overactive bladder (OAB) | March 20, 2018 |
| propranolol hydrochloride | Hemangiol™ | proliferating infantile hemangioma | January 29, 2019 |
| propylthiouracil | Halycil™ | medical management of hyperthyroidism; in conjunction with radioiodine to hasten recovery while awaiting the effects of radiation; control of thyrotoxicosis prior to surgery; management of a thyroid storm in addition to other therapeutic measures | May 31, 2022 |
| ramipril + hydrochlorothiazide | Altace HCT® | hypertension | December 17, 2008 |
| ranolazine | Corzyna™ | add-on symptomatic treatment for inadequately controlled stable angina | February 1, 2022 |
| ravulizumab | Ultomiris® | atypical hemolytic uremic syndrome, to inhibit complement mediated thrombotic microangiopathy | September 22, 2023 |
| ravulizumab | Ultomiris® | treatment of adult patients with anti-acetylcholine receptor (AChR) anti-body positive generalized myasthenia gravis (gMG) | April 17, 2024 |
| reslizumab | Cinqair™ | add-on maintenance treatment for adults with severe eosinophilic asthma | April 28, 2020 |
| rifaximin | Zaxine® | hepatic encephalopathy | February 6, 2018 |
| riociguat | Adempas® | chronic thromboembolic pulmonary hypertension (CTEPH) | March 10, 2015 |
| riociguat | Adempas® | pulmonary arterial hypertension (PAH) | May 2, 2017 |
| risankizumab | Skyrizi® | moderate to severe plaque psoriasis in adults | May 5, 2020 |
| risankizumab | Skyrizi® | adults with moderately to severely active Crohn's disease who have had an inadequate response, intolerance, or demonstrated dependence to corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies | May 30, 2024 |
| risperidone | Perseris® | schizophrenia in adults | August 16, 2022 |
| rituximab | Rituxan® | relapsing remitting multiple sclerosis | November 27, 2018 |
| rituximab | Riximyo™ | severely active rheumatoid arthritis (RA), relapsing remitting multiple sclerosis (RRMS) | August 20, 2020 and August 19, 2021 |
| rituximab | Ruxience™ | severely active rheumatoid arthritis (RA), relapsing remitting multiple sclerosis (RRMS), the induction of remission in severely active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) |
August 20, 2020 |
| rituximab | Truxima™ | severely active rheumatoid arthritis (RA), relapsing remitting multiple sclerosis (RRMS), the induction of remission in severely active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) |
August 20, 2020 |
| rivaroxaban | Xarelto® | thromboembolic events (venous), pulmonary embolism (PE) | September 30, 2014 and April 1, 2020 |
| romosozumab | Evenity™ | for the treatment of osteoporosis in postmenopausal women at high risk for fractures | December 12, 2023 |
| rotigotine | Neupro® | Parkinson's disease | November 13, 2018 |
| ruxolitinib | Jakavi® | chronic graft-versus-host disease (cGvHD) in patients aged 12 years and older | November 23, 2023 |
| ruxolitinib | Jakavi® | acute graft-versus-host disease (cGvHD) in patients aged 12 years and older | November 23, 2023 |
| sacubitril-valsartan | Entresto™ | heart failure | March 6, 2018 and October 5, 2020 |
| sarilumab | Kevzara | rheumatoid arthritis | October 17, 2017 and June 30, 2020 |
| satralizumab | Enspryng® | for the treatment of neuromyelitis optica spectrum disorders (NMOSD) | November 1, 2023 |
| saxagliptin; saxagliptin-metformin | Onglyza®, Komboglyze™ | type 2 diabetes mellitus | August 5, 2014 |
| sebelipase alfa | Kanuma® | lysosomal acid lipase deficiency (LAL-D) | April 5, 2023 |
| secukinumab | Cosentyx® | psoriasis, moderate to severe plaque | July 28, 2016 |
| secukinumab | Cosentyx® | psoriatic arthritis | April 24, 2018 |
| selexipag | Uptravi® | pulmonary arterial hypertension | October 30, 2018 |
| semaglutide | Ozempic® | type 2 diabetes mellitus | December 15, 2020 |
| semaglutide | Rybelsus® | type 2 diabetes mellitus | January 31, 2023 |
| simeprevir | Galexos™ | chronic hepatitis C (CHC) genotype 1 infection | October 28, 2014 |
| siponimod | Mayzent™ | secondary progressive multiple sclerosis (SPMS) | January 25, 2022 |
| sitagliptin; sitagliptin-metformin | Januvia®, Janumet®, Janumet® XR | type 2 diabetes mellitus | August 5, 2014 |
| sodium phenylbutyrate and ursodoxicoltaurine (PB-TURSO) | Albrioza™ | amyotrophic lateral sclerosis (ALS) | July 19, 2024 (delisting) July 19, 2023 |
| sodium zirconium cyclosilicate | Lokelma™ | hyperkalemia in adults | August 18, 2020 |
| sofosbuvir | Sovaldi® | chronic hepatitis C (CHC) | February 4, 2020 |
| sofosbuvir-velpatasvir | Epclusa™ | chronic hepatitis C (CHC) | February 4, 2020 |
| sofosbuvir-velpatasvir-voxilaprevir | Vosevi™ | chronic hepatitis C (CHC) | February 4, 2020 |
| somatrogon | Ngenla™ | long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (known as, growth hormone deficiency) | May 2, 2023 |
| somatropin | Genotropin® | growth hormone deficiency, adults | August 5, 2014 |
| somatropin | Genotropin® | growth hormone deficiency, pediatrics | August 5, 2014 |
| somatropin | Genotropin® | growth hormone deficiency, Turner syndrome | August 5, 2014 |
| somatropin | Omnitrope® | growth hormone deficiency or chronic renal insufficiency, pediatric | April 10, 2018 |
| stiripentol | Diacomit™ | severe myoclonic epilepsy in infancy (Dravet syndrome) | July 7, 2015 |
| tapentadol | Nucynta® | severe pain | May 22, 2019 |
| teduglutide | Revestive® | short bowel syndrome (SBS) | August 15, 2017 |
| telaprevir | Incivek® | chronic hepatitis C virus infection in patients co-infected with HIV | October 10, 2013 |
| telbivudine | Sebivo® | chronic hepatitis B infection in patients with liver disease | March 27, 2008 |
| tenofovir alafenamide fumarate | Vemlidy™ | chronic hepatitis B | December 18, 2018 |
| tenofovir disoproxil fumarate | Viread® | chronic hepatitis B | November 27, 2018 |
| teriflunomide | Aubagio™ | relapsing-remitting multiple sclerosis (RRMS) | December 9, 2014 |
| tesamorelin | Egrifta® | excess visceral adipose tissue (VAT) in treatment-experienced adult human immunodeficiency virus (HIV)-infected patients with lipodystrophy | December 13, 2016 |
| tezepelumab | Tezspire™ | as an add-on maintenance treatment in adults and adolescents 12 years of age and older with severe asthma | December 14, 2023 |
| ticagrelor | Brilinta® | in combination with low-dose acetylsalicylic acid (ASA) for the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI occurring at least one year ago) and a high-risk of developing an atherothrombotic event | September 5, 2017 |
| tildrakizumab | Ilumya™ | moderate-to-severe plaque psoriasis in adult patients | February 22, 2022 |
| tinzaparin | Innohep® | venous thromboembolism (VTE) associated with cancer | February 14, 2017 |
| tiotropium bromide | Spiriva® Respimat® | chronic obstructive pulmonary disease (COPD) | April 5, 2016 |
| tiotropium-olodaterol | Inspiolto™ Respimat® | chronic obstructive pulmonary disease (COPD) | April 5, 2016 |
| tocilizumab | Actemra® | moderate to severely active polyarticular juvenile idiopathic arthritis (pJIA) | December 9, 2014 |
| tocilizumab | Actemra® | rheumatoid arthritis | February 19, 2016 |
| tocilizumab | Actemra® | giant cell arteritis | March 12, 2019 |
| tofacitinib | Xeljanz™ | rheumatoid arthritis (RA) | January 31, 2017, November 17, 2020 |
| tofacitinib | Xeljanz™ | ulcerative colitis (UC) | November 17, 2020 |
| tolvaptan | Samsca® | hyponatremia, non-hypovolemic | August 15, 2013 |
| tralokinumab | Adtralza® | moderate-to-severe atopic dermatitis | December 13, 2022 |
| travoprost ophthalmic solution | Izba™ | open-angle glaucoma | May 29, 2018 |
| triamcinolone hexacetonide | N/A | symptoms of subacute and chronic inflammatory joint diseases in adults and adolescents | November 16, 2021 |
| trientine | Mar-Trientine | Wilson's disease | May 17, 2022 |
| trientine | Waymade-Trientine | Wilson's disease | October 25, 2022 |
| ulipristal acetate | Fibristal® | uterine fibroids | October 2, 2018 |
| umeclidinium | Incruse™ Ellipta® | chronic obstructive pulmonary disease (COPD) | March 15, 2016 |
| umeclidinium-vilanterol | Anoro™ Ellipta™ | chronic obstructive pulmonary disease (COPD) | August 11, 2015 |
| upadacitinib | Rinvoq® | moderate to severe active rheumatoid arthritis | November 29, 2022 |
| upadacitinib | Rinvoq® | moderate to severe psoriatic arthritis (PsA) | November 29, 2022 |
| upadacitinib | Rinvoq® | moderate to severe atopic dermatitis | November 23, 2023 |
| upadacitinib | Rinvoq® | treatment of adult patients with moderately to severely active Crohn's disease (CD) | September 17, 2024 |
| upadacitinib | Rinvoq® | treatment of moderately to severely active ulcerative colitis (US) in adults who have demonstrated prior treatment failure, i.e., an inadequate response to, loss of response to, or intolerance to at least one of conventional and/or biologic therapy | October 3, 2024 |
| ustekinumab | Stelara® | moderate to severe psoriatic arthritis (PsA) | May 26, 2015 |
| ustekinumab | Stelara® | Crohn's disease | August 27, 2019 |
| ustekinumab | Stelara® | moderate to severe active ulcerative colitis in adults | January 17, 2023 |
| ustekinumab | Jamteki™ | treatment of adult patients with active psoriatic arthritis and for the treatment of chronic moderate to severe plaque psoriasis in adult patients | May 30, 2024 |
| ustekinumab | Wezlana™ and Steqeyma® | plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis (Wezlana) plaque psoriasis, psoriatic arthritis, and Crohn's disease (Steqeyma) |
September 17, 2024 |
| vancomycin oral | generics | Clostridium difficile infection | December 18, 2019 |
| vedolizumab | Entyvio™ | Crohn's disease | May 2, 2017 |
| vedolizumab | Entyvio™ | ulcerative colitis | May 2, 2017 |
| vedolizumab | Entyvio™ | Crohn's disease, ulcerative colitis | April 12, 2022 |
| vericiguat | Verquvo® | treatment of symptomatic chronic heart failure (HF) in adult patients with reduced ejection fraction who are stabilized after a recent HF decompensation event requiring hospitalization and/or intravenous diuretic therapy. Verquvo should be taken in combination with other standard of care therapies for HF. | October 15, 2024 |
| voretigene neparvovec | Luxturna® | vision loss due to inherited retinal dystrophy (IRD) caused by confirmed biallelic RPE65 mutations | February 28, 2023 |
| vortioxetine | Trintellix™ | major depressive disorder (MDD) | July 6, 2021 |
| Subject of review | Drugs included in review | Date | Supporting information and documents |
|---|---|---|---|
| Alzheimer’s disease |
|
April 2016 | Alzheimer's drug therapy review reports and DBC recommendation |
| Attention deficit hyperactivity disorder (ADHD) |
|
April 2017 |
Attention Deficit Hyperactivity Disorder (ADHD) Drug Therapy Review Reports |
| Cancer-associated thrombosis (CAT) | LMWH (originator and biosimilar):
|
March 22, 2022 | Cancer-associated thrombosis therapeutic review (PDF, 2.04MB) |
| Chronic obstructive pulmonary disease (COPD) | All drug classes covered under COPD:
|
July 2020 |
|
| Multiple sclerosis (relapsing remitting) |
|
January 25, 2022 | |
| Overactive bladder (OAB) |
|
August 2016 | |
| Reference Drug Program | All drugs covered under the Reference Drug Program:
|
June 2016 | RDP review reports and DBC recommendation |
